ES2722110T3 - Composición farmacéutica que comprende una suspensión de células totales obtenida de folículo piloso y factores de crecimiento derivados de plasma para tratar la alopecia - Google Patents
Composición farmacéutica que comprende una suspensión de células totales obtenida de folículo piloso y factores de crecimiento derivados de plasma para tratar la alopecia Download PDFInfo
- Publication number
- ES2722110T3 ES2722110T3 ES15723437T ES15723437T ES2722110T3 ES 2722110 T3 ES2722110 T3 ES 2722110T3 ES 15723437 T ES15723437 T ES 15723437T ES 15723437 T ES15723437 T ES 15723437T ES 2722110 T3 ES2722110 T3 ES 2722110T3
- Authority
- ES
- Spain
- Prior art keywords
- growth factors
- plasma
- derived growth
- subject
- cell suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/985—Skin or skin outgrowth, e.g. hair, nails
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0627—Hair cells
- C12N5/0628—Hair stem cells; Hair progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Método de obtención de una composición que comprende una suspensión celular que comprende células progenitoras del pelo (HPC) de un sujeto humano y factores de crecimiento derivados de plasma, que comprende las siguientes etapas: a. incubar una muestra de tejido aislado que comprende al menos un folículo piloso completo del sujeto, preferiblemente de la región occipital de la cabeza del sujeto, en una suspensión de factores de crecimiento derivados de plasma, obtenidos preferiblemente del sujeto; durante un periodo de tiempo de entre 15 minutos y 1 hora a una temperatura de aproximadamente 37ºC; b. homogeneizar la composición celular de la etapa a) por medio de un homogeneizador mecánico o manual tal como un homogeneizador Potter; y c. retirar los fragmentos de tejido del producto de la etapa b); preferiblemente mediante filtración; en el que en este método las células del tejido obtenido a partir de la muestra de la etapa a) no se digieren enzimáticamente; en el que la suspensión de factores de crecimiento derivados de plasma se obtiene separando la fracción celular de la sangre del plasma para formar el coágulo que a su vez contiene los factores de crecimiento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14382150.2A EP2937098A1 (en) | 2014-04-24 | 2014-04-24 | A pharmaceutical composition comprising a suspension of total cells obtained from hair follicle and plasma derived growth factors for promoting hair follicle regeneration |
PCT/EP2015/058993 WO2015162282A1 (en) | 2014-04-24 | 2015-04-24 | A pharmaceutical composition comprising a suspension of total cells obtained from hair follicle and plasma derived growth factors for promoting hair follicle regeneration |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2722110T3 true ES2722110T3 (es) | 2019-08-07 |
Family
ID=50679982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES15723437T Active ES2722110T3 (es) | 2014-04-24 | 2015-04-24 | Composición farmacéutica que comprende una suspensión de células totales obtenida de folículo piloso y factores de crecimiento derivados de plasma para tratar la alopecia |
Country Status (4)
Country | Link |
---|---|
US (1) | US20170042941A1 (es) |
EP (2) | EP2937098A1 (es) |
ES (1) | ES2722110T3 (es) |
WO (1) | WO2015162282A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018175630A1 (en) * | 2017-03-23 | 2018-09-27 | The Regents Of The University Of California | Stimulation of hair growth by senescent cells and senescence associated secretory phenotype |
CN116831983B (zh) * | 2023-09-02 | 2023-12-29 | 潍坊市人民医院(潍坊市公共卫生临床中心) | 一种浓缩生长因子复合凝胶制剂、制备方法及生发应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030082576A (ko) * | 2001-01-29 | 2003-10-22 | 아데란스 리서치 인스티튜트 인코포레이티드 | 모낭 전구세포의 주사에 의한 모낭 신생 |
US20110305671A1 (en) * | 2010-06-10 | 2011-12-15 | Alvi Armani Genomics Inc. | Cell Compositions and Methods for Hair Follicle Generation |
CN102586177A (zh) * | 2012-02-15 | 2012-07-18 | 北京雍禾植发技术研究院 | 治疗秃发的毛囊干细胞培养方法及注射器 |
CN103497930A (zh) * | 2013-09-29 | 2014-01-08 | 李玉红 | 毛乳头细胞的培养方法 |
-
2014
- 2014-04-24 EP EP14382150.2A patent/EP2937098A1/en not_active Withdrawn
-
2015
- 2015-04-24 US US15/306,273 patent/US20170042941A1/en not_active Abandoned
- 2015-04-24 WO PCT/EP2015/058993 patent/WO2015162282A1/en active Application Filing
- 2015-04-24 ES ES15723437T patent/ES2722110T3/es active Active
- 2015-04-24 EP EP15723437.8A patent/EP3139946B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2937098A1 (en) | 2015-10-28 |
US20170042941A1 (en) | 2017-02-16 |
EP3139946A1 (en) | 2017-03-15 |
WO2015162282A1 (en) | 2015-10-29 |
EP3139946B1 (en) | 2018-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019002805A1 (es) | Expresión selectiva de un transgene de tejidos. | |
PH12017502283A1 (en) | A method of treatment | |
MX2022008523A (es) | Compuestos que interactuan con glicanos y metodos de uso. | |
AR079889A1 (es) | Antagonistas de wnt y metodos de tratamiento y deteccion | |
CO6450609A2 (es) | Implantes de apófisis espinosas y métodos asociados | |
MX2017010377A (es) | Andamios e implantes de tejidos suaves biológicamente funcionales. | |
SG10201808104RA (en) | Cenicriviroc for the treatment of fibrosis | |
WO2015112793A3 (en) | Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof | |
EP4364799A3 (en) | Mesenchymal stem cell-derived extracellular vesicles and their medical use | |
MX2016016756A (es) | Terapia con células madre en patologías endometriales. | |
MX2017002469A (es) | Composiciones de matrices extracelulares. | |
DE102015209007A8 (de) | Knochenersatzmaterialien, Verfahren zur Herstellung eines Knochenersatzmaterials sowie medizinische Kits zur Behandlung von Knochendefekten | |
MX2016005824A (es) | Metodo de cultivo celular. | |
EP4275746A3 (en) | Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use | |
MX2017008454A (es) | Peptidos y su uso en el tratamiento de la piel. | |
BR112017014098A2 (pt) | métodos de isolamento de plaquetas | |
ES2722110T3 (es) | Composición farmacéutica que comprende una suspensión de células totales obtenida de folículo piloso y factores de crecimiento derivados de plasma para tratar la alopecia | |
NZ723169A (en) | Fgf-18 in graft transplantation and tissue engineering procedures | |
PH12016500708A1 (en) | Recombinant glycoproteins and uses thereof | |
EP3708653A4 (en) | ARTIFICIAL ADAPTIVE TISSUE AND METHOD FOR MANUFACTURING THEREOF, METHOD FOR MANUFACTURING ARTIFICIAL SKIN AND AGENTS FOR FAT CELLS | |
EA201792603A1 (ru) | Ангиогенез с использованием стимулированных плацентарных стволовых клеток | |
MX2020002551A (es) | Metodos, composiciones y celulas para preparar proteina surfactante d (sp-d). | |
AR099556A1 (es) | Implante que contiene fgf-18 | |
MX2016014628A (es) | Metodo para expandir las celulas madre adultas de sangre entera. | |
RU2013148644A (ru) | Способ восстановления целостности тонкой кишки |